Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3
- PMID: 14678774
- DOI: 10.1016/j.nbd.2003.08.016
Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3
Abstract
Patients with Gaucher disease have been classified as type 1 nonneuronopathic, type 2 acute neuronopathic, and type 3 chronic neuronopathic phenotypes. Increased quantities of glucocerebroside and glucosylsphingosine (glucopsychosine) are present in the brain of type 2 and type 3 Gaucher patients. Galactosylsphingosine has previously been shown to be neurotoxic in globoid cell leukodystrophy (Krabbe disease). To determine whether glucosylsphingosine is also neurotoxic, we examined its effect on cultured cholinergic neuron-like LA-N-2 cells. When these cells were exposed to 1, 5, or 10 microM glucosylsphingosine for a period of 18 h, they became shriveled, neurite outgrowth was suppressed, and the activities of the lysosomal enzymes glucocerebrosidase, sphingomyelinase, and beta-galactosidase were reduced in a dose-dependent manner. Acetylcholine in cells exposed to glucosylsphingosine also declined. Cells switched to glucosylsphingosine-free medium partially recovered. The data suggest that accumulation of glucosylsphingosine contributes to neuronal dysfunction and destruction in patients with neuronopathic Gaucher disease.
Similar articles
-
Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype.Mol Genet Metab. 2002 Aug;76(4):262-70. doi: 10.1016/s1096-7192(02)00117-8. Mol Genet Metab. 2002. PMID: 12208131
-
Glucosylsphingosine accumulation in mice and patients with type 2 Gaucher disease begins early in gestation.Pediatr Res. 2000 Aug;48(2):233-7. doi: 10.1203/00006450-200008000-00018. Pediatr Res. 2000. PMID: 10926300
-
Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?Mol Genet Metab. 2003 Jun;79(2):104-9. doi: 10.1016/s1096-7192(03)00071-4. Mol Genet Metab. 2003. PMID: 12809640
-
Neuronal forms of Gaucher disease.Handb Exp Pharmacol. 2013;(216):405-19. doi: 10.1007/978-3-7091-1511-4_20. Handb Exp Pharmacol. 2013. PMID: 23563668 Review.
-
Ophthalmic manifestations of Gaucher disease: the most common lysosomal storage disorder.Br J Ophthalmol. 2019 Mar;103(3):315-326. doi: 10.1136/bjophthalmol-2018-312846. Epub 2019 Jan 5. Br J Ophthalmol. 2019. PMID: 30612093 Review.
Cited by
-
GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice.Mol Neurodegener. 2024 Mar 7;19(1):22. doi: 10.1186/s13024-024-00713-z. Mol Neurodegener. 2024. PMID: 38454456 Free PMC article.
-
The Consequences of GBA Deficiency in the Autophagy-Lysosome System in Parkinson's Disease Associated with GBA.Cells. 2023 Jan 3;12(1):191. doi: 10.3390/cells12010191. Cells. 2023. PMID: 36611984 Free PMC article. Review.
-
Galactosyl- and glucosylsphingosine induce lysosomal membrane permeabilization and cell death in cancer cells.PLoS One. 2022 Nov 21;17(11):e0277058. doi: 10.1371/journal.pone.0277058. eCollection 2022. PLoS One. 2022. PMID: 36409725 Free PMC article.
-
Potential Role of Sphingolipidoses-Associated Lysosphingolipids in Cancer.Cancers (Basel). 2022 Oct 5;14(19):4858. doi: 10.3390/cancers14194858. Cancers (Basel). 2022. PMID: 36230781 Free PMC article. Review.
-
Neuronopathic Gaucher disease: Beyond lysosomal dysfunction.Front Mol Neurosci. 2022 Aug 3;15:934820. doi: 10.3389/fnmol.2022.934820. eCollection 2022. Front Mol Neurosci. 2022. PMID: 35992201 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
